Rating Change
JP Morgan analysts initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) with a rating of Overweight on October 16, 2026.
new coverageNASDAQ:PRAX
JP Morgan Initiates Coverage on Praxis Precision Medicines, Inc. (PRAX) with Overweight
JP Morgan analysts initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) with a rating of Overweight on October 16, 2026.
At publication ·
What changed
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) · new coverage
- Firm
- JP Morgan
- Rating
- Overweight
- Price at event
- $241.76
- Market capitalization
- $5.7B
At a glance
Key takeaways
- JP Morgan initiated coverage of Praxis Precision Medicines (PRAX) on October 16, 2026 with an Overweight rating.
- The stock trades at $241.76 with a market capitalization of $5.7 billion in the healthcare sector.
Market Context
Praxis Precision Medicines, Inc. operates in the Healthcare sector. The stock currently trades at $241.76 with a market capitalization of $5.7B.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Praxis Precision Medicines, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Praxis Precision Medicines, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 16, 2026 | JP Morgan | Overweight | N/A |
| Oct 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 15, 2026 | UBS | Buy | N/A |
| Oct 06, 2026 | BTIG | Buy | N/A |
| Oct 06, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PRAX Stock Page
Frequently Asked Questions
What does the Overweight rating mean for PRAX?
A rating of Overweight from JP Morgan reflects the analyst's outlook on Praxis Precision Medicines, Inc. (NASDAQ:PRAX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PRAX forecast page.